Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Iran-backed militias reassert power in Iraq, proving the Islamic axis is still standing - 2‘Wu-Tang Forever: The Final Chamber’ tour — How to get tickets, presale times, concert dates and more
- 3At UN climate conference, some activists and scientists want more talk on reforming agriculture
- 4CDC advisory panel delays vote on hepatitis B vaccines after unruly meeting
- 5'The Real Housewives of Rhode Island' 1st teaser trailer unveiled: Which Bachelor Nation star is part of the cast? And when does it premiere?
- 21 Things You Ought to Never Tell Your Childless Companion
- A Russian fighting for Ukraine conned the Kremlin out of $500,000 by faking his own death
- Katz, IDF: We assassinated IRGC intelligence chief Majid Khademi
- You finally got a doctor's appointment. Here's how to get the most out of it
- 3 Italian City Cars That Outsmarted Regulations and Rivals
- NMG signs new graphite supply deal with Canadian Government
- France, Germany, Italy summon Iranian envoys over 'unbearable, inhumane' regime crackdown
- Dozens of hidden star streams found in the outskirts of our Milky Way galaxy
- Miss Thailand Pageant Contestant's Veneers Fall Out During Speech on Stage
